Understanding Signal Management in Pharmacovigilance: A Key Pillar of Drug Safety
In today’s dynamic regulatory environment, continuous monitoring of a medicine’s safety profile is more critical than ever. One of the most essential activities that…
Read more →Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products
In March 2022, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Considerations for the Development of Chimeric Antigen Receptor (CAR)…
Read more →Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of pharmaceutical products. One of its key…
Read more →ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and effectiveness of medical devices. One of its key…
Read more →Electronic Submission Template for Medical Device De Novo Requests
The U.S. Food and Drug Administration (FDA) has released guidance on the importance of diversity in clinical trials to ensure that study populations reflect…
Read more →Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA
The U.S. Food and Drug Administration (FDA) has issued guidance to enhance the transparency and consistency of benefit-risk assessments in the regulatory review process…
Read more →